Skip to main content
SpringerLink
Log in

Efficacy of Prophylactic Minocycline Treatment for Skin Toxicities Induced by Erlotinib Plus Gemcitabine in Patients with Advanced Pancreatic Cancer: A Retrospective Study

  • Original Research Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Background

Erlotinib has been reported as being associated with a high incidence of skin toxicities such as acneiform rash, paronychia, and xerosis.

Objective

The aim of this study was to evaluate the efficacy of prophylactic minocycline treatment for the skin toxicities induced by erlotinib as compared with deferred minocycline treatment in patients with pancreatic cancer treated with erlotinib plus gemcitabine.

Methods

A total of 96 patients were studied retrospectively, of whom 44 received prophylactic minocycline between August 2012 and June 2013 and 52 received deferred minocycline treatment between August 2011 and July 2012 at the National Cancer Center Hospital East, Kashiwa, Japan. In the prophylactic minocycline group, 200 mg/day oral minocycline was prophylactically administered during the treatment period.

Results

The incidence rate of acneiform rash and xerosis of any grade during the first 6 weeks of treatment was significantly reduced in the prophylactic minocycline group compared with the deferred minocycline treatment group (47.7 vs. 80.8 %, p < 0.001; 2.3 vs. 19.2 %, p = 0.01). Multivariate analysis identified prophylactic minocycline as a significant independent factor associated with the incidence of acneiform rash and xerosis of any severity (odds ratio [OR] 0.16, 95 % confidence interval [CI] 0.06–0.46, p < 0.001; OR 0.11, 95 % CI 0.01–0.90, p = 0.04).

Conclusion

Prophylactic minocycline appears to be useful for the management of erlotinib-related acneiform rash and xerosis during chemotherapy in patients with advanced pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Moore MJ, Goldstein D, Hamm J, Figer A, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of canada clinical trial group. J Clin Oncol. 2007;25:1960–6.

    CAS  PubMed  Google Scholar 

  2. Okusaka T, Furuse J, Funakoshi A, et al. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci. 2011;102:425–31.

    CAS  PubMed  Google Scholar 

  3. Nakagawa K, Kudoh S, Ohe Y, et al. Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR). J Thorac Oncol. 2012;7:1296–303.

    CAS  PubMed  Google Scholar 

  4. Galimont-Collen AF, Vos LE, Lavrijsen AP, et al. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer. 2007;43:845–51.

    CAS  PubMed  Google Scholar 

  5. Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007;25:5390–6.

    CAS  PubMed  Google Scholar 

  6. Lacouture ME, Michell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:1351–7.

    CAS  PubMed  Google Scholar 

  7. Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007;13:3913–21.

    CAS  PubMed  Google Scholar 

  8. Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group study BR.21. J Clin Oncol. 2008;26:2350–7.

    CAS  PubMed  Google Scholar 

  9. Jatoi A, Green EM, Rowland KM, et al. Clinical predictors of severe cetuximab-induced rash: observation from 933 patients enrolled in North Central Cancer Treatment Group study N0147. Oncology. 2009;77:120–3.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinations of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22:3238–47.

    CAS  PubMed  Google Scholar 

  11. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22:3238–47.

    Google Scholar 

  12. Nanney LB, Stoscheck CM, King LE Jr, et al. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol. 1990;94:742–8.

    CAS  PubMed  Google Scholar 

  13. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Targ Oncol. 2009;4:107–19.

    Google Scholar 

  14. Pastore S, Mascia F, Mariotti F, et al. ERK1/2 regulates epidermal chemokine expression and skin inflammation. J Immunol. 2005;174:5047–56.

    CAS  PubMed  Google Scholar 

  15. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6:803–12.

    CAS  PubMed  Google Scholar 

  16. Pruzanski W, Greenwald RA, Street IP, et al. Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline. Biochem Pharmacol. 1992;44:1165–70.

    CAS  PubMed  Google Scholar 

  17. Amin AR, Attur MG, Thakker GD, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci. 1996;93:14014–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  18. Dreno B, Bettoli V, Ochsendorf F, et al. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol. 2004;14:391–9.

    PubMed  Google Scholar 

  19. Vincent JA, Mohr S. Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes. 2007;56:224–30.

    Article  CAS  PubMed  Google Scholar 

  20. Shu KY, Kindler HL, Medenica M, et al. Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol. 2006;154:191–2.

    PubMed  Google Scholar 

  21. Stintzing S, Kapaun C, Laubender RP, et al. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer. 2013;132:236–45.

    CAS  PubMed  Google Scholar 

  22. Migliaccio A, Castoria G, Di Domenico M, et al. Steroid-induced androgen receptor-oestradiol receptor-Src complex triggers prostate cancer cell proliferation. EMBO J. 2000;19:5406–17.

    PubMed Central  CAS  PubMed  Google Scholar 

  23. Migliaccio A, Castoria G, Di Domenico M, et al. Crosstalk between EGFR and extranuclear steroid receptors. Ann NY Acad Sci. 2006;1089:194–200.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This manuscript was prepared without the help of any funding source. A. Shinohara, M. Ikeda, H. Okuyama, M. Kobayashi, H. Funazaki, S. Mitsunaga, S. Shimizu, I. Ohno, H. Takahashi, Y. Ichida, K. Takahashi, T. Okusaka and S. Saitoh have no conflicts of interests to declare.

Author information

Authors and Affiliations

  1. Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan

    Akira Shinohara, Misaki Kobayashi, Hideki Funazaki, Yasuhiko Ichida, Kunio Takahashi & Shinichiro Saitoh

  2. Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan

    Masafumi Ikeda, Hiroyuki Okuyama, Shuichi Mitsunaga, Satoshi Shimizu, Izumi Ohno & Hideaki Takahashi

  3. Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan

    Takuji Okusaka

Authors
  1. Akira Shinohara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masafumi Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroyuki Okuyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Misaki Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hideki Funazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shuichi Mitsunaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Satoshi Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Izumi Ohno
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hideaki Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yasuhiko Ichida
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kunio Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Takuji Okusaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Shinichiro Saitoh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masafumi Ikeda.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shinohara, A., Ikeda, M., Okuyama, H. et al. Efficacy of Prophylactic Minocycline Treatment for Skin Toxicities Induced by Erlotinib Plus Gemcitabine in Patients with Advanced Pancreatic Cancer: A Retrospective Study. Am J Clin Dermatol 16, 221–229 (2015). https://doi.org/10.1007/s40257-015-0116-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-015-0116-x

Keywords

Search

Navigation